ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 2040 • ACR Convergence 2024

    Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice

    Martin Michaud1, Laurent Sailler2, Mélanie LEMEU3, Brice CASTEL4, Fabienne Vacheret5, Laurent Prudhomme6 and Grégory Pugnet7, 1Clinique Saint Exupery, Toulouse, France, 2CHU Toulouse, Toulouse, France, 3CH Albi, Albi, France, 4CH TARBES, Tarbes, France, 5CH Perpignan, Perpignan, France, 6CH Castres, Castres, France, 7Toulouse Rangueil University Hospital, Toulouse, France

    Background/Purpose: Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory syndrome marked by recurrent pericardial inflammation after an initial episode of acute pericarditis. Standard treatment involves…
  • Abstract Number: 0855 • ACR Convergence 2024

    Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study

    Alexandra Kachaner1, Arthur Mageau1, Tiphaine Goulenok2, Chrystelle Francois2, Marie-Paule Chauveheid2, Thomas Papo1 and Karim Sacré1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hôpitaux de Paris, Paris, France

    Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled…
  • Abstract Number: 2043 • ACR Convergence 2024

    Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study

    Fatma Zehra Avci1, Feyza Nur Azman2, Elif Sila Unsal3 and Serdal Ugurlu4, 1Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, 4Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) typically begins in childhood. It has been demonstrated that colchicine can reduce FMF attacks, prevent the development of amyloidosis, and…
  • Abstract Number: 0340 • ACR Convergence 2023

    Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study

    Chiara Gasteiger1, Maria Lobo2, Robin Stanley1, Lun Shen Wong1, Rachel Murdoch1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand

    Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…
  • Abstract Number: 1941 • ACR Convergence 2023

    Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations

    Eduardo Martin-Nares1, Beatriz E. Sánchez-Hernández2, Peter Grayson3, Jose Crispin1, Daniel Montante-Montes de Oca2, Andrea Hinojosa-Azaola1, Gabriela Hernandez-Molina1, Elia Apodaca4, Emma M. Groarke5, Jesús Delgado-de la Mora2, Silvia Méndez-Flores6, Armando Gamboa-Domínguez2, Bhavisha Patel7 and Marcela Ferrada8, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 4Department of Oncology and Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, 6Department of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 7National Institutes of Health, Beltsville, MD, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…
  • Abstract Number: 0713 • ACR Convergence 2023

    IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis

    Edwin Ulises Cortez-Domínguez1, Gabriela Hernandez-Molina1, Norma Ofelia Uribe-Uribe2, María J Lizardo-Thiebaud2 and Eduardo Martin-Nares1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Constrictive pericarditis (CP) is a type of diastolic heart failure characterized by impaired cardiac filling due to the presence of an inelastic pericardium. Histologically,…
  • Abstract Number: 1942 • ACR Convergence 2023

    Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases

    Carmen Lasa1, Joy Selene Osorio2, David Martínez-Lopez3, Carmen Alvarez Reguera4, Virginia Portilla5, Jose Cifrian6, Ivan Ferraz Amaro7 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 6Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, 7Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: Patients with rheumatic immune-mediated inflammatory diseases (rheumatic-IMID) with latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at anincreased risk of developing active tuberculosis…
  • Abstract Number: 1004 • ACR Convergence 2023

    Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario

    Amanda Steiman1, Taucha Inrig2, Katie Lundon3, Jocelyne Murdoch4 and Rachel Shupak5, 1Sinai Health System, Toronto, ON, Canada, 2St. Michael's Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Arthritis Society, Toronto, ON, Canada, 5St. Michael's Hospital/University of Toronto, Toronto, ON, Canada

    Background/Purpose: A  shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…
  • Abstract Number: 2520 • ACR Convergence 2023

    Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis

    Carmen Lasa1, Raul Fernandez-Ramon2, Jorge Javier Gaitán2, Jose Luis Martin-Varillas3, Rosalía Demetrio2, Ivan Ferraz Amaro4, Santos Castañeda5 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Hospital de la Princesa, Madrid, Spain, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Sarcoidosis is a disease with heterogeneous clinical presentation and course. The objective of this study is the identification of clinical phenotypes using cluster analysis.…
  • Abstract Number: 1005 • ACR Convergence 2023

    Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial

    Lesley E. Jackson1, Jinoos Yazdany2, Kiara Aaron1, Sarah Goglin3, Mary Margaretten2, David Chae4, Jeffrey Curtis1, Diana Paez5, Gary Cutter1, Kenneth Saag1 and Maria I. ("Maio") Danila6, 1University of Alabama at Birmingham, Birmingham, AL, 2University of California San Francisco, San Francisco, CA, 3University of California San Francisco, Burlingame, CA, 4Tulane University School of Public Health & Tropical Medicine, New Orleans, LA, 5University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, 6University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: In the wake of the COVID-19 pandemic, telemedicine rapidly became standard of care for people with rheumatic diseases. Observational data on effectiveness and acceptability…
  • Abstract Number: 1061 • ACR Convergence 2023

    Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology

    Chani-mi Lee1, Margaret Wang2, Aarthi Rajkumar1, Cassandra Calabrese3 and Leonard Calabrese3, 1University Hospital, Cleveland, OH, 2Case Western Reserve University, Cleveland, OH, 3Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH

    Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
  • Abstract Number: 1071 • ACR Convergence 2023

    No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

    Madeline O'Sullivan1, Grant Cannon1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel4, Jessica A Walsh5, Punyasha Roul6, Bryant England6, Ted R Mikuls7, Joshua Baker8 and Tawnie Braaten4, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4University of Utah, Salt Lake City, UT, 5Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 6University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
  • Abstract Number: 1079 • ACR Convergence 2023

    Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements

    Tawnie Braaten1, Selene Rubino1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel1, Jessica A Walsh4, Shardool Patel5 and Grant Cannon5, 1University of Utah, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
  • Abstract Number: 1149 • ACR Convergence 2023

    Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series

    Tessalyn Morrison1, Taylor Lakusta-Wong1, Chantal Roy-Hewitson1, Jeanne Gosselin2 and Alana Nevares3, 1University of Vermont, Burlington, VT, 2University of Vermont Medical Center, Waterbury, VT, 3University of Vermont, Essex Junction, VT

    Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
  • Abstract Number: 0047 • ACR Convergence 2023

    Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis

    Marie Robert1, Nader Yatim2, Arthur Mageau3, Nicolas Charles4, Tiphaine Goulenok2, Tom Dott1, Violaine Saint Andre1, Darragh Duffy1 and Karim Sacre3, 1Institut Pasteur Paris, Paris, France, 2Assistance Publique Hopitaux de Paris, Paris, France, 3Université Paris Cité, Paris, France, 4INSERM, Paris, France

    Background/Purpose: Sarcoidosis is an inflammatory disease characterized by granuloma tissue lesions that most commonly affect the lungs, but can target any other organ. While the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology